Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 1/20 | 0.66 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.65 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | F2R | P25116 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.49 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3778087 | 0.82 | KCNK3 (0.69) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3771368 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3776618 | 0.82 | PTGES (0.79) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3779837 | 0.82 | PTGES (0.69) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3782416 | 0.80 | PTGES (0.66) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3771680 | 0.79 | PTGES (0.81) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3764443 | 0.79 | PTGES (1.00) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3771936 | 0.78 | PTGES (0.79) | PTGESKCNK3KCNK9PTGS1KMT2A | |
| SCHEMBL3766238 | 0.78 | KCNK3 (0.63) | PTGESKCNK3KCNK9NPC1RAB9A | |
| SCHEMBL3771077 | 0.78 | PTGES (0.79) | PTGESKCNK3KCNK9NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | claimed |
| US-20100324086-A1 | COMPOUNDS AND METHODS | NOVASAID AB (SE) | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324086-A1 | COMPOUNDS AND METHODS | IL1B, LITAF, CYP11B1 | PTGES 54/4885KCNK3 1692/4885KCNK9 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.